Novartis acquires experimental breast cancer drug for $3 billion

GateUser-bd883c58 · 2026-04-02T05:16:22+00:00

Novartis announces acquisition of Synnovation Therapeutics, purchasing the PI3Kα inhibitor SNV4818 to advance treatment innovation for HR+/HER2- breast cancer and other solid tumors. The deal includes a $2 billion upfront payment and up to $1 billion in milestone payments.

GateUser-bd883c58

2026-04-02 05:16:22

Abstract generation in progress

Ask AI · How will Novartis’ massive acquisition accelerate innovation in solid tumor therapies?

On March 20, Novartis announced that it has reached an agreement with Synnovation Therapeutics to acquire pan-mutant selective PI3Kα inhibitor SNV4818, with the goal of exploring next-generation treatment options for patients with HR+/HER2- breast cancer and potential other solid tumor indications. SNV4818 is an oral drug that is currently in Phase I/II clinical trials for breast cancer and other advanced solid tumors. Under the terms of the agreement, Novartis will pay Synnovation Therapeutics a $2.0 billion upfront payment and up to $1.0 billion in milestone payments to acquire Pikavation Therapeutics, Synnovation’s wholly owned subsidiary.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.